Crispr Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Wednesday before the open, rising from 74 to 81. If you were tuned in to IBD Live this morning, you would have heard the team chatting about this particular stock.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's proprietary RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Decades of market research reveals that the best stocks typically have an 80 or better RS Rating as they begin their biggest runs.
See How IBD Helps You Make More Money In Stocks
Crispr Therapeutics is not currently near a perfect buying area. It has recently cleared overhead resistance of key moving averages. See if the stock goes on to build a promising consolidation that could ignite a new run.
Crispr Therapeutics showed -53% EPS growth in its most recent report. Sales rose 74%. Look for the next report on or around Jul. 29.
Crispr Therapeutics holds the No. 90 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics and Dynavax Technologies are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
